The prefilled syringe drug molecule market is set for significant expansion, with projected sales increasing from USD ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

SMi is delighted to announce its 4 th annual Pre-Filled Syringes West Coast conference coming to San Diego, USA on the 3 rd and 4 th June 2019. The competitive PFS market has sparked great ...

Evan Seigerman, an analyst from BMO Capital, reiterated the Buy rating on Regeneron (REGN – Research Report). The associated price target ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

Net Income per Share: $12.46, an 8% increase from the prior year. DUPIXENT Global Revenue: $3.8 billion, a 24% increase on a constant currency basis. EYLEA HD and EYLEA Net Sales: $1.54 billion ...

Dupixent had another strong quarter with ... aflibercept 2-milligram launch and the recent launch of a branded pre-filled syringe. The EYLEA HD clinical profile continues to look differentiated ...

Beyond that, Regeneron is pointing to next year when it hopes to gain approval for Eylea HD in retinal vein occlusion and will bring the product to market in a pre-filled syringe. “Next year we ...

Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new indications (nasal polyposis) and younger patients.